Northbrook, Ill, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., today announced that Robert E. Dudley, Ph.D., chief executive officer of Clarus Therapeutics will present an update on the Company and its investigational oral testosterone (T) replacement product, Rextoro™ (formerly CLR-610), at the 32nd annual J.P. Morgan Healthcare Conference. Clarus' presentation will take place at 11:30am PT on Monday, January 13, 2014 at the Westin St Francis Hotel in San Francisco, CA.
The J.P. Morgan Healthcare Conference is one of the most widely attended healthcare investment conferences in the industry, bringing together global industry leaders, more than 300 emerging and established companies, and over 4,000 members of the investment community. Attendance at the J.P. Morgan Healthcare Conference is by invitation only.
About Clarus Therapeutics
Clarus is a privately held biopharmaceutical company focused on the development and commercialization of our oral T-replacement product, Rextoro™ (formerly CLR-610). Two Phase 3 trials for Rextoro have been successfully completed. According to the American Urological Association, 10% of men 40-to-60 years of age, and 20% over the age of 60 have low T levels. Common symptoms associated with low T may include mild depression, reduced sex drive and erectile function, increased body fat, and decreased energy, lean body mass, muscle strength and bone mineral density. For more information, please visit: www.clarustherapeutics.com.
Source: Clarus Therapeutics